Abstract
A 69-year-old male was diagnosed in February 2004 with stage IV extranodal marginal zone B cell lymphoma involving the mediastinal nodes, lung parenchyma and bone marrow with high LDH. Shortness of breath developed following the 5th course of Rituximab-CHOP chemotherapy (cyclophosphamide, Vincristine, Doxorubicin, Prednisolone). Bronchoscopy guided transbronchial lung biopsy revealed interstitial thickening and type II pneumocyte activation, compatible with interstitial pneumonitis. After treatment with prednisolone a complete resolution of the dyspnea was observed. The patient was well on routine follow-up at the outpatient clinic, with no progression of lymphoma or interstitial pneumonitis.
MeSH terms
-
Aged
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biopsy
-
Cyclophosphamide / adverse effects
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / adverse effects
-
Doxorubicin / therapeutic use
-
Humans
-
Lung Diseases, Interstitial / chemically induced*
-
Lung Diseases, Interstitial / diagnostic imaging
-
Lung Diseases, Interstitial / pathology*
-
Lung Diseases, Interstitial / surgery
-
Lymphoma, B-Cell, Marginal Zone / drug therapy*
-
Male
-
Prednisone / adverse effects
-
Prednisone / therapeutic use
-
Rituximab
-
Tomography, X-Ray Computed
-
Vincristine / adverse effects
-
Vincristine / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone